Piper Sandler initiated coverage on AVITA Medical with a new price target
$RCEL
Medical/Dental Instruments
Health Care
Piper Sandler initiated coverage of AVITA Medical with a rating of Overweight and set a new price target of $27.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/11/2024 | Buy → Neutral | BTIG Research | |
| 6/27/2023 | $23.00 | Overweight | Cantor Fitzgerald |
4 - AVITA Medical, Inc. (0001762303) (Issuer)
3 - AVITA Medical, Inc. (0001762303) (Issuer)
4 - AVITA Medical, Inc. (0001762303) (Issuer)
VALENCIA, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a company specializing in commercial-stage regenerative medicine and pioneering devices for wound care management and skin restoration, today announced it has entered into an exclusive distribution agreement with Revolution Surgical Pty Ltd. This agreement marks an important milestone in our expansion into the Australian and New Zealand markets. Under the terms of the agreement, Revolution Surgical will serve as the exclusive distributor of the RECELL® product platform, including RECELL GO® (pending regulatory approval), in Australia and New Zealand. This partnership aims to enhance the avail
VALENCIA, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O'Toole, Chief Financial Officer, on November 12, 2024, at 2:00 p.m. Pacific Standard Time (November 13, 2024, at 9:00 a.m. Australian Eastern Daylight Time). The webinar presentation will cover financial and business results from our recent third-quarter 2024 earnings webcast and will conclude with a Q&A se
VALENCIA, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today reported financial results for the third quarter ended September 30, 2024. Financial Results and Recent Business Updates Commercial revenue of $19.5 million, an increase of approximately 44% compared to the same period in 2023Gross profit margin of 83.7%On July 31, 2024, entered into a multi-year development and distribution agreement with Regenity Biosciences that provides AVITA Medical with the exclusive rights to market, sell, and distribute Cohealyx™, a
10-Q - AVITA Medical, Inc. (0001762303) (Filer)
8-K - AVITA Medical, Inc. (0001762303) (Filer)
S-8 - AVITA Medical, Inc. (0001762303) (Filer)
SC 13G - AVITA Medical, Inc. (0001762303) (Subject)
SC 13G - AVITA Medical, Inc. (0001762303) (Subject)
SC 13G/A - AVITA Medical, Inc. (0001762303) (Subject)
4 - AVITA Medical, Inc. (0001762303) (Issuer)
4 - AVITA Medical, Inc. (0001762303) (Issuer)
4 - AVITA Medical, Inc. (0001762303) (Issuer)
BTIG Research downgraded Avita Medical from Buy to Neutral
Cantor Fitzgerald initiated coverage of Avita Medical with a rating of Overweight and set a new price target of $23.00
Piper Sandler initiated coverage of AVITA Medical with a rating of Overweight and set a new price target of $27.00
VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary, effective July 1, 2024. Ms. Kelsey has more than two decades of executive legal experience with expertise in M&A, securities, and governance, along with a strong track record building and leading global regulatory and compliance programs. Previously, she served as Chief Legal Officer and Secretary for Amyris, Inc. (NASDAQ:AMRS) and General Counse
VALENCIA, Calif. and MELBOURNE, Australia, June 15, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced the appointment of David O'Toole as its new Chief Financial Officer, effective June 15, 2023. O'Toole is an accomplished financial executive with more than 30 years of experience in global corporate finance, capital markets, and accounting across biotech and life sciences companies. He has a demonstrated track record of developing and executing successful growth strategies in a number of public
VALENCIA, Calif. and MELBOURNE, Australia, March 23, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today the appointment of Robert McNamara to its Board of Directors, effective April 1, 2023. Mr. McNamara is an accomplished senior executive with over 25 years of leadership experience in public and privately held companies in the medical device and technology industries. His extensive experience in operations and financial management spans across early stage, high growth, and mature companies. He
AVITA Medical (NASDAQ:RCEL) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 3 1 0 0 Last 30D 0 1 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 2 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $19.0, a high estimate of $25.00, and a low estimate of $9.00. A negative shift in sentiment is evident as analyst
VALENCIA, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today reported financial results for the third quarter ended September 30, 2024. Financial Results and Recent Business Updates Commercial revenue of $19.5 million, an increase of approximately 44% compared to the same period in 2023Gross profit margin of 83.7%On July 31, 2024, entered into a multi-year development and distribution agreement with Regenity Biosciences that provides AVITA Medical with the exclusive rights to market, sell, and distribute Cohealyx™, a
VALENCIA, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that it will report its third quarter 2024 financial results after the close of the U.S. financial markets on Thursday, November 7, 2024. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, November 8, 2024, at 8:30 a.m. Australian Eastern Daylight Time) to discuss its financial results and recent business highlights. The live webcast will be accessible under the Events & Presentations section of the A
VALENCIA, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today reported financial results for the second quarter ended June 30, 2024. Financial Results and Recent Business Updates Commercial revenue of $15.1 million, an increase of approximately 29% compared to the same period in 2023Gross profit margin of 86.2%RECELL GO™ premarket approval (PMA) supplement approved by the FDA on May 29, 2024; first case completed on May 31, 2024Submitted PMA supplement for RECELL GO mini™, designed to address smaller wounds, on June